Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
We celebrate our unique history as the pioneers of scientific breakthroughs that have an incredible track record of improving lives. And yet, our ambitions are bigger and bolder. Together, we are united in a bold quest to solve the world’s most complex health challenges and serve society.
Our ability to bring transformative medicines to patients depends on the positive experience, engagement and resilience of everyone who works here. Our employees are the heart of Genentech and the driving force behind the progress that brings important new medicines to the people who need them. We believe a great people experience is critical for revolutionizing healthcare and living Our Promise. That’s why we’re committed to cultivating an environment where people feel valued, included and able to thrive.
Investing in Landmark Health Equity Research
Inequity in our healthcare system is an urgent issue. For too long, Black, Latinx and other marginalized patients have suffered vastly disparate health outcomes. At Genentech, we strive to put patients—and their experiences—at the center of everything we do.
We undertook a landmark study to elevate the perspectives of these medically disenfranchised individuals and reveal how this long-standing inequity impacts their relationships with the healthcare system as a whole.
Genentech Champions Health Screenings to Help Improve Patient Outcomes
A cancer screening awareness campaign focused on Black and Latina women, created “by the community, for the community.” We collaborated with local health systems and community organizations from across New York City to launch Love Letters for Cancer Screening, a multicultural initiative.
Its goal is to reduce inequities in care, using the power of love to spread messages about the importance of cancer screening for women. Love Letters for Cancer Screening was also launched in partnership with Cancer Screen Week partners, the American Cancer Society, Optum and StandUptoCancer.
We Focus on Access So You Can Focus on Health
Genentech shares your commitment to advancing patient care and reducing barriers to treatment. From product information and patient access to screening initiatives, Genentech provides resources to help you and your patients, whether your focus is getting one patient on a Genentech therapy or on improving the entire patient population.
Our resources may be able to help health care providers, administrators and/or practice staff assist patients after a Genentech medicine has been prescribed.
Research and Insights
- Healthcare Disparities 2022 Insights Report
This report encourages conversations that address the needs of populations that have been underserved for too long. - Patient Financial Burden: Considerations for Oncology Care and Access White Paper
Learn about one organization’s approach to addressing financial toxicity.
Industry Trends
- Trends in Specialty Drug Benefits Report
This report details a wide range of specialty drug benefit design choices, financial and clinical strategies, goals, challenges, concerns and needs. - Advancing Inclusive Clinical Trial Representation
At Genentech, we are deeply committed to addressing barriers to clinical study participation and advancing inclusive research.
Screening and Education Resources
- Love Letters for Cancer Screening
This cancer screening awareness campaign aims to improve outcomes among Black and Latina women. - Stroke Awareness
This campaign provides information and resources to help patients understand stroke and recognize the warning signs.
Contact
Dee Humm
Principal National Account Executive
Genentech
402-415-6128
hummd@gene.com